| Name | BI-78D3 |
| Description | BI-78D3, a competitive JNK inhibitor. IC50 of BI-78D3 is 280 nM that displays > 100 fold selectivity over p38α, and have no activity at mTOR and PI-3K. |
| Cell Research | Cells are subjected to a dose range of doxorubicin concentrations in the presence or absence of a non-toxic dose (10 nM) of the small molecule JIP1-inhibitor BI-78D3. (Only for Reference) |
| In vitro | BI-78D3 Inhibits JNK interacting protein 1 (JIP1)-JNK binding and prevents JNK substrate phosphorylation[2]. |
| In vivo | In animal studies, BI-78D3 not only blocks JNK dependent Con A-induced liver damage but also restores insulin sensitivity in mouse models of type 2 diabetes[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.27 mM), Sonication is recommended. Ethanol : 1.9 mg/mL (5.01 mM), Sonication is recommended. DMSO : 37.9 mg/mL (99.9 mM), Sonication is recommended.
|
| Keywords | JNK | Inhibitor | inhibit | BI-78D-3 | BI-78D3 | BI78D3 | BI 78D3 |
| Inhibitors Related | Astragaloside IV | Teneligliptin hydrobromide | Berberine hydrogen sulphate | SP600125 | Chloranil | (-)-Bornyl acetate | Benzbromarone | Anisomycin | Chloramphenicol | Metacetamol | Berberine sulfate | Benzyl salicylate |
| Related Compound Libraries | Highly Selective Inhibitor Library | Anti-Colorectal Cancer Compound Library | Apoptosis Compound Library | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Pain-Related Compound Library | Kinase Inhibitor Library | Anti-Ovarian Cancer Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max |